文献速递临床试验与 GCP流行病学与生物统计

自我标识为去中心化临床试验的系统综述

Adoption of 'decentralized' clinical trial terminology: a systematic review of self-identified decentralized clinical trials.
PubMed 文献 · Trials · 2026-07-31

该研究系统检索MEDLINE、Embase、CENTRAL及临床试验注册平台,纳入28项明确自我标识为去中心化临床试验的研究,全部发表于2021年后且数量逐年增加。这些试验均为单国研究,96%来自高收入国家,主要使用电子知情同意和远程数据采集设备,患者报告结局使用频繁。去中心化要素组合无统一模式,报告质量有待提高。

要点

  • 自我标识为去中心化临床试验的研究数量自2021年起逐年增加但总体仍少。
  • 96%的去中心化试验来自高收入国家,均为单国研究,提示实施或报告存在不公平。
  • 电子知情同意使用率71%,远程结局数据采集设备使用率75%。

核心结论

  • 自监管机构2018年引入去中心化临床试验术语以来,明确自我标识的去中心化试验自2021年起增多但总体数量仍低。
  • 这些试验主要在高收入国家开展,提示实施或报告可能存在不公平。
  • 没有单一去中心化要素组合占主导,不同疾病领域和实施方式存在差异。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase和CENTRAL从建库至2024年9月9日,获得4357篇文献。
  • 两名评价员独立双份筛选标题、摘要和全文,双份提取关键数据。
  • 另于2024年7月18日检索国际临床试验注册平台和ClinicalTrials.gov以识别未发表和正在进行的去中心化试验。

主要发现

  • 28项试验中54%已完成、46%正在进行,中位样本量为900(IQR 192-1470)。
  • 所有试验均为单国研究,96%来自高收入国家,多数在北美。
  • 药物干预最常见(43%)。
  • 在评估的9个去中心化组成部分中,电子知情同意用于71%的试验,结局数据采集设备用于75%。
  • 患者报告结局在86%的试验中收集,并在61%的试验中作为主要结局。

关键数值与推荐

  • 仅4项试验在注册记录中描述自身为去中心化。
  • 电子健康记录用于筛选在75%的试验中不明确,集中监查在79%的试验中不明确。

临床怎么用

  • 临床研究者可参考电子知情同意和远程数据采集设备作为去中心化试验的常见要素。
  • 开展去中心化试验时应关注中低收入国家的实施公平性。
  • 需改进报告以区分去中心化要素的未使用与未报告。

局限性

  • 仅纳入明确自我标识为去中心化的试验,可能遗漏采用去中心化要素但未如此标识的研究。
  • 多数试验来自高收入国家,结果外推至其他地区受限。
  • 部分去中心化要素(如电子健康记录筛选、集中监查)使用情况不明确,影响评价准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In recent years, trials have leveraged digital tools and remote methods to improve patient access and diversity, streamline operations, enhance data collection, and reduce costs and timelines. Regulatory terminology has defined these as decentralized clinical trials. While many earlier trials incorporated one or more decentralized elements (e.g. e-consent, remote monitoring), little is known about recent trials that adopt multiple elements and explicitly identify as decentralized. OBJECTIVE: To determine, in trials explicitly identifying as decentralized, which decentralized elements they use, where they are occurring, and which therapeutic areas and interventions they involve. METHODS: A search of MEDLINE, Embase, and CENTRAL from inception to September 9, 2024, yielded 4357 articles. Two reviewers independently and in duplicate screened titles, abstracts, and full texts to identify trials explicitly described as decentralized. Key data were extracted in duplicate to ensure accuracy. Additionally, the International Clinical Trials Registry Platform and ClinicalTrials.gov were searched on July 18, 2024, to identify unpublished and ongoing decentralized clinical trials. RESULTS: Thirty-three publications (28 unique trials) met inclusion, all published since 2021, with numbers increasing annually. Only four trials described themselves as decentralized in their trial registration records. Of the 28 included trials, 54% were completed and 46% were ongoing, with a median sample size of 900 (IQR 192-1470). All were single-country studies, 96% from high-income countries, mostly in North America. Pharmacological interventions were most common (43%). Among nine decentralized components evaluated, e-consent was used in 71% of trials, and devices for outcome data collection in 75%. It was unclear if electronic health records were used for screening in 75%, and centralized monitoring in 79% of trials. Patient-reported outcomes were frequent, collected in 86% of trials and serving as the primary outcome in 61%. CONCLUSION: Since regulators introduced the terminology in 2018, adoption among trials explicitly identifying as decentralized has increased since 2021, although the overall number remains low. These trials occur mainly in high-income countries, suggesting potential inequities in implementation or reporting. No single decentralized element combination dominated, indicating variability in how decentralized approaches are implemented across disease areas and interventions. Improved reporting is needed to distinguish between underuse and underreporting of decentralized elements. PROSPERO REGISTRATION NUMBER: CRD42024571898.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wright, Berwanger, Rajaram, et al. Adoption of 'decentralized' clinical trial terminology: a systematic review of self-identified decentralized clinical trials. Trials. 2026. PMID: 42934714. doi:10.1186/s13063-026-09922-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。